InnoMedica was able to demonstrate the great potential of the nanotransport system with the development of first applications in the fields of oncology, neurology and infectiology.
In addition, national and international research collaborations are already underway and are to be expanded further. InnoMedica is interested in collaborating with research institutions that would like to investigate new applications of the nanotransport system in combination with already known or also new active substances. Also conceivable are cooperations with other pharmaceutical companies that would like to apply their active ingredients in a more targeted way with the help of InnoMedica’s nanotransport system and optimise the benefit/side-effect profile. Its solid expertise in the field of nanomedicine as well as its production experience enable InnoMedica to respond to individual needs and to flexibly tailor solutions upon request.
This highly effective chemotherapy can convince even in late-stage cancers. Talidox substantially improves the benefit/side-effect profile without causing any serious side-effects.
Fostering regeneration instead of merely preventing degeneration – InnoMedica’s novel and innovative therapeutic approach introduces a paradigm shift to neurology. It promises to revolutionize the therapeutic prognosis for patients with Parkinson’s Disease or Amyotrophic Lateral Sclerosis (ALS).
By developing a vaccine against Covid-19, InnoMedica takes responsibility as a pharmaceutical company and reacts quickly to the volatile pandemic situation thanks to its flexibility, immunological competency, and own manufacturing facility.